My Journey as a Heart Transplantation Patient …and What I Want Providers to Know: Part 1
JCF is honored to share this Patient Experience Series over the next 3 weeks. Part I is below. The full story will be published in the May 2024 issue and online under our Patient and Caregiver Center at www.jcfonline.com. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 24, 2024 Category: Cardiology Authors: Mark Booras Source Type: research
Sodium-Glucose Co-transporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have proven benefits on clinical outcomes in patients with heart failure (HF).1-6 However, this class of medications increases the risk of mycotic genital infections (MGIs) and urinary tract infections (UTIs), particularly within the first 3-6 months after their initiation.7,8,9 In the EMPEROR-Preserved and EMPEROR-Reduced trials, MGIs and UTIs were among the 3 most common adverse events in the empagliflozin group,1,2 highlighting the clinical relevance of these infections. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 24, 2024 Category: Cardiology Authors: Angela Duvalyan, Ricardo M. La Hoz, Darren K McGuire, Mark H. Drazner Tags: Review Article Source Type: research
Five Year Experience from a Cardiovascular Physician and APP Leadership Development Program
As payment and clinical care models place increased emphasis on patient-centered care, multidisciplinary teams, public health, wellness, and social determinants of health, clinical leadership is increasingly recognized as essential to high quality, safe and efficient operations. (1,2) (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 19, 2024 Category: Cardiology Authors: Warren S. Levy Tags: Brief Report Source Type: research
Body Mass Index Distribution Among Patients with Heart Failure and Reduced Ejection Fraction: Implication for Future Trials
Obesity related heart failure with preserved ejection fraction (HFpEF) has been well described as a distinct phenotype associated with cardiac structural and functional alterations as well as a systemic proinflammatory milieu. Semaglutide, a long-acting glucagon like peptide (GLP)-1 receptor agonist, was recently assessed in patients with HF and an LVEF of ≥45% and obesity (without type 2 diabetes) in the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and Heart Failure with preserved Ejection Fraction) trial and was shown to improve symptoms, and exercise capacity, compared with placebo. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 16, 2024 Category: Cardiology Authors: Javed Butler, Ambica Nair, Muhammad Shahzeb Khan Tags: Research Letter Source Type: research
Association of Psychosocial Risk Factors With Quality of Life and Readmissions 1-Year After LVAD Implantation
Among patients with advanced heart failure (HF), treatment with a left ventricular assist device (LVAD) improves health-related quality of life (HRQOL). We investigated the association between psychosocial risk factors, HRQOL, and outcomes after LVAD implantation. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 15, 2024 Category: Cardiology Authors: Jeffrey Wang, Alexis K Okoh, Yuxuan Chen, Rebecca S. Steinberg, Apoorva Gangavelli, Krishan J. Patel, Yi-An Ko, Jeffrey D. Alexis, Shivani A. Patel, David J. Vega, Mani Daneshmand, Ersilia M. DeFilippis, Khadijah Breathett, Alanna A. Morris Source Type: research
Palliative Care Education in Cardiovascular Disease Fellowships: A National Survey of Program Directors
Palliative care (PC) is an essential component of high-quality cardiovascular disease (CVD) care. However, little is known about the current state of PC education in CVD training including attitudes towards integration in training and implementation among program leadership. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 12, 2024 Category: Cardiology Authors: Sarah Godfrey, Jill M. Steiner, Abdulla A. Damluji, Ramya Sampath, Sarah Chuzi, Haider Warraich, Ashok Krishnaswami, Gwen Bernacki, Sarah Goodlin, Richard Josephson, John Mulrow, Caroline Doherty Source Type: research
The Association between Pre-operative Pectoralis Muscle Quantity and Outcomes after Cardiac Transplantation
: Sarcopenia is underappreciated in advanced heart failure and is not routinely assessed. In patients receiving a left ventricular assist device (LVAD), preoperative sarcopenia, defined using CT-derived pectoralis muscle area index (muscle area indexed to body surface area), is an independent predictor of post-operative mortality. The association between preoperative sarcopenia and outcomes after heart transplant (HT) is unknown. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 12, 2024 Category: Cardiology Authors: Elissa Driggin, Alice Chung, Erin Harris, Abraham Bordon, Salwa Rahman, Gabriel Sayer, Koji Takeda, Nir Uriel, Mathew S. Maurer, Jay Leb, Kevin Clerkin Source Type: research
Troponin in Heart Failure: Innocent Bystander or Harbinger of Risk?
Heart failure (HF) with reduced ejection fraction (HFrEF) is a leading contributor to morbidity and mortality.1,2 Several medical therapies are proven to extend survival, prevent hospitalizations, and improve quality of life in HFrEF.2 Yet despite their availability, patients with worsening HF have exceedingly high risk for 30-day mortality and rehospitalization.1,3 With the rising prevalence of HF and hospital readmissions globally,1 population-level screening strategies are imperative to identify and potentially mitigate adverse risk in HFrEF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 12, 2024 Category: Cardiology Authors: Anand Shah, Vishal N. Rao Tags: Editor's Comment Source Type: research
The impact of local programmatic decisions on outcomes in transplant-listed adults with congenital heart disease
Heart failure is the leading cause of death for adults with congenital heart disease (ACHD), complicated by unclear efficacy of guideline-directed medical therapy in this population1 –3 and a lack of consensus on appropriate timing for orthotopic heart transplant (OHT) referral.4 Once referred for transplant, the path remains unclear for these patients, as it has been previously shown that ACHD heart transplant candidates experienced longer wait times and higher waitlist morta lity than non-ACHD candidates. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 12, 2024 Category: Cardiology Authors: Armaan F. Akbar, Benjamin L. Shou, Ahmet Kilic, Ari M. Cedars Source Type: research
Natriuretic Peptides and Prognosis in Patients with Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events
Prognosis of individuals with and without an established heart failure (HF) diagnosis and similarly elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels is not well known. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 11, 2024 Category: Cardiology Authors: Muhammad Shahzeb Khan, James L. Januzzi, Yuxi Liu, Jialin Xu, Wayne Shaw, Naveed Sattar, Kenneth W. Mahaffey, Bruce Neal, Michael K Hansen, Javed Butler Source Type: research
Patient Focus: Moving Beyond Step Count. An Explanation of Real-world walking behaviors are associated with early-stage heart failure: a Project baseline Health Study.
In this issue of the Journal of Cardiac Failure, Dr. Sooyoon Shin and colleagues look at whether information from wearable devices, or activity trackers, could improve how a medical team monitors activity limitations for people who are at risk of developing heart failure symptoms.1 (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 9, 2024 Category: Cardiology Authors: Spencer Carter, Jennifer T. Thibodeau Source Type: research
Remote Follow-up in a Heart Failure Pragmatic Trial: Insights From the CONNECT-HF
Traditional randomized controlled trials (RCTs) are necessary for establishing causality between interventions and outcomes, forming the basis for clinical guidelines.1 However, the requirement for study-specific in-person study visits by participants to collect accurate clinical outcomes poses a burden on participants and sites, resulting in high costs and limiting eligible participants to those with the ability to travel to visits.2 Remote follow-up methods, such as utilizing central call centers for participant-reported events or site reports using medical record query, have potential for enhanced trial efficiency, redu...
Source: Journal of Cardiac Failure - April 8, 2024 Category: Cardiology Authors: Satoshi Shoji, Lisa A. Kaltenbach, Bradi B. Granger, Gregg C. Fonarow, Hussein Al-Khalidi, Nancy M. Albert, Javed Butler, Larry A. Allen, G. Michael Felker, Robert W. Harrison, Marat Fudim, Adam J. Nelson, Christopher B. Granger, Adrian F. Hernandez, Adam Source Type: research
Estimating the Proportion of Heart Failure Admissions Potentially Eligible for Hospital at Home
Hospital at home (HaH) is an emerging care model where patients requiring hospitalization receive inpatient-level care at home. Services include twice daily nursing visits with laboratory collection, intravenous medications, patient education, and other acute care services. Current regulations also require daily physician or advanced practice provider visits and other hospital services such as radiology and physical therapy. Programs sometimes require patients to have a certain level of independence or a caregiver to provide support between nursing visits. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 6, 2024 Category: Cardiology Authors: Hubert B. Haywood, Aubrey Jolly Graham, David Chermak, Aditya Achanta, Javed Butler, Gregg C. Fonarow, Stephen J. Greene Tags: Research Letter Source Type: research
The Wallet Biopsy: Medical Crowdfunding for Heart Transplantation
In this study, we sought to describe the state of crowdfunding for individuals being evaluated for heart transplantation. Using the search term heart transplant, 1000 GoFundMe campaigns were reviewed. After exclusions, 634 (63.4%) campaigns were included. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 6, 2024 Category: Cardiology Authors: ERSILIA M. DEFILIPPIS, ADHYA MEHTA, FATIMAH A. ALKHUNAIZI, CHRISTY N. TAYLOR, JOS É LOPEZ, LAURA MCLAUGHLIN, VANESSA BLUMER, NASRIEN E. IBRAHIM Tags: Brief Report Source Type: research
Genetic referral patterns and outcomes among patients with non-ischemic cardiomyopathy requiring advanced therapies
Patients with advanced heart failure (HF) due to a range of cardiomyopathy (CMP) subtypes often require advanced therapies including left ventricular assist devices (LVADs) or orthotopic heart transplantation (OHT). Nonischemic etiologies underlie roughly half of patients with advanced HF requiring advanced therapies.1,2 Over the last two decades, experts have increasingly recognized the prognostic and therapeutic impact of defining specific CMP endotypes toward the goal of personalized medicine. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 5, 2024 Category: Cardiology Authors: Rebecca Castro, Emir Veledar, Leslee Shaw, Donna Mancini, Noah Moss, Veronica Fettig, Amy R. Kontorovich, Anuradha Lala Tags: Research Letter Source Type: research
